Genistein, A Phytoestrogen, Delays the Transition to Dementia in Prodromal Alzheimer's Disease Patients

J Alzheimers Dis. 2024;101(s1):S275-S283. doi: 10.3233/JAD-240308.

Abstract

Alzheimer's disease is recognized as a complex condition influenced by multiple factors, necessitating a similarly multifaceted approach to treatment. Ideally, interventions should prioritize averting the progression to dementia. Given the chronic nature of the disease, long-term management strategies are required. Within this framework, lifestyle modifications and dietary supplements emerge as appealing options due to their minimal toxicity, limited side effects, and cost-effectiveness. This study presents findings from a double-blind, placebo-controlled bicentric pilot clinical trial, demonstrating the significant cognitive preservation associated with genistein, a phytoestrogen found in soy and various other dietary sources, among individuals with prodromal Alzheimer's disease. Our prior investigation utilizing APP/PS1 mice elucidated the specific mechanisms through which genistein operates, including anti-amyloid-β, antioxidant, anti-inflammatory, and antiapoptotic effects. These findings underscore the potential of identifying bioactive compounds from dietary sources for the management of Alzheimer's disease.

Keywords: Aging; Alzheimer’s disease; dementia; genistein; soya supplements; treatment..

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Alzheimer Disease* / prevention & control
  • Animals
  • Dementia / prevention & control
  • Disease Progression
  • Double-Blind Method
  • Female
  • Genistein* / therapeutic use
  • Humans
  • Male
  • Mice
  • Phytoestrogens* / therapeutic use
  • Pilot Projects
  • Prodromal Symptoms*

Substances

  • Genistein
  • Phytoestrogens